. Inhibition of oncogenic KRAS (hereafter KRAS*), the earliest lesion in disease development that is present in more than 90% of PDACs, and its signalling surrogates has yielded encouraging preclinical results with experimental agents [2] [3] [4] . However, KRAS*-independent disease recurrence following genetic extinction of Kras* in mouse models anticipates the need for co-extinction strategies 5, 6 . Multiple oncogenic processes are initiated at the cell surface, where KRAS* physically and functionally interacts to direct signalling that is essential for malignant transformation and tumour maintenance. Insights into the complexity of the functional cellsurface-protein repertoire (surfaceome) have been technologically limited until recently and-in the case of PDAC-the genetic control of the function and composition of the PDAC surfaceome in the context of KRAS* signalling remains largely unknown. Here we develop an unbiased, functional target-discovery platform to query KRAS*-dependent changes of the PDAC surfaceome, which reveals syndecan 1 (SDC1, also known as CD138) as a protein that is upregulated at the cell surface by KRAS*. Localization of SDC1 at the cell surface-where it regulates macropinocytosis, an essential metabolic pathway that fuels PDAC cell growth-is essential for disease maintenance and progression. Thus, our study forges a mechanistic link between KRAS* signalling and a targetable molecule driving nutrient salvage pathways in PDAC and validates oncogene-driven surfaceome annotation as a strategy to identify cancer-specific vulnerabilities.
To annotate changes in cell-surface proteins driven by KRAS* signalling, we used a doxycycline-inducible Kras* mouse model of PDAC (hereafter, iKras*) to acutely induce and thereafter extinguish expression of the activated oncogene, Kras G12D (ref. 7 ). Stable isotope labelling by/with amino acids in cell culture (SILAC)-based mass spectrometry was used to identify changes in the proteome that are induced by KRAS* extinction in three independent cell culture isolates from iKras* tumours. In brief, cells were labelled with either heavy isotope C 6 -Lys, and surface proteome changes were quantified using liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) 24 h after doxycycline withdrawal (Fig. 1a) , a time point at which there is significant loss of RAS activity (Extended Data Fig. 1a ) without obvious changes in cell morphology or proliferation rate. Comparison of KRAS*-ON with KRAS*-OFF paired samples (Extended Data Fig. 1b -e) identified 221 differentially expressed plasma membrane proteins 8, 9 (according to http://compartments.jensenlab.org)-196 of which were upregulated and 25 of which were downregulated (Supplementary Tables 1, 2)-suggesting that KRAS* primarily drives surface protein enrichment rather than depletion. The top-20 species most significantly upregulated by KRAS* (Extended Data Fig. 1f, g ) represent a broad spectrum of known effectors, several of which are known to be upregulated and have a functional role in PDAC pathogenesis. Our proteomic analysis also identified many cell-surface-associated proteins regulated by KRAS*. Ingenuity pathway analysis (IPA) revealed that many KRAS*-upregulated cell-surface proteins are involved in biological processes that are activated in PDAC, including the axonal guidance signalling pathway 10 (Fig. 1b and Supplementary Table 3) , which supports the notion that KRAS* is a major driver of molecular reprogramming in PDAC.
To assess the functional relevance of our findings to human disease, we compared the mouse surfaceome data with human surfaceome data from 11 PDAC cell lines 11 . We chose 110 proteins that are potentially regulated by KRAS* that are also enriched in human PDAC cells (Supplementary Tables 1, 4) , and 37 surfaceome genes that are highly expressed in human PDAC cells (Supplementary Table 4) to generate a pooled, lentiviral short-hairpin RNA (shRNA) library. We conducted an in vivo loss-of-function screen using a previously described barcoding methodology 12 in orthotopically implanted tumours derived from three iKras* mouse cell lines (Fig. 1a) . Next-generation sequencing analysis revealed full representation of library complexity, high correlation among tumour replicates and expected behaviour of positive (PSMA1 and RPL30) and negative (Renilla luciferase (Luc)) controls (Extended Data Fig. 2a-c) . The screens uncovered 79 genes that were significantly depleted in at least 1 of the 3 models; 36 of these genes were common to at least two models (Extended Data Fig. 2d and Supplementary Table 4 ). Among 11 hits that were depleted in all three models, SDC1-a member of the heparin sulfate proteoglycan family-was also among the most significantly enriched in the plasma membrane during KRAS* expression ( Fig. 1c and Supplementary  Table 4 ). Further, among the top-ten most-enriched surfaceome proteins modulated by KRAS*, three belonged to the heparin sulfate proteoglycan family (SDC1, SDC4 and GPC1) (Extended Data Fig. 1g ), which prompted us to select SDC1 as a top-priority candidate as a mediator of KRAS*-driven cellular reprogramming in PDAC.
Representative mass spectra indicated that membrane expression of SDC1 was upregulated in KRAS*-ON relative to KRAS*-OFF conditions (Fig. 1d ). This was confirmed by immunofluorescence and flow Letter reSeArCH cytometry analysis, in which KRAS* extinction led to a rapid decrease of SDC1 membrane expression that was reversed upon re-expression of KRAS* ( Fig. 1e and extended Data Fig. 3a) . Membrane localization of other surface proteins, such as α-catenin (CTNNA1) and calcium pump pan PMCA ATPase, was not altered following KRAS* inactivation, which suggests that it had a specific effect on SDC1 (Extended Data Fig. 3b ). KRAS* inactivation did not affect Sdc1 mRNA abundance or total protein expression (Extended Data Fig. 3c-e) . In vivo, KRAS* expression in the iKras G12D p53 L/+ PDAC model (p53 is also known as Trp53) induced membrane enrichment of SDC1 in premalignant lesions and advanced tumours, whereas its extinction in established tumours resulted in depletion of SDC1 surface expression (Fig. 1f) . Comparable induction of membrane-localized SDC1 was observed in the LSL-Kras G12D model (also known as the KC model) (Extended Data Fig. 3f) .
In a primary human PDAC tissue array, we detected SDC1 in premalignant lesions (early pancreatic intraepithelial neoplasia) and in tumour-adjacent lesions reminiscent of chronic pancreatitis, as well as in advanced premalignant lesions and invasive carcinomas (Extended Data Fig. 3g, h ). Several published human microarray datasets have reported significantly increased SDC1 expression in PDAC tissue compared with normal pancreas (Extended Data Fig. 3i ), which implicates SDC1 in PDAC pathogenesis. Enrichment of surface SDC1 in very early disease could result from oncogenic signalling or inflammatory responses associated with pancreatitis. To differentiate, we induced chronic pancreatitis in iKras* mice with caerulein, followed by doxycycline treatment to induce KRAS* expression. Whereas metaplastic lesions were similarly positive for the ductal marker CK19 before and after doxycycline treatment, SDC1 was induced mostly on oncogene induction, but not by caerulein (Extended Data Fig. 3j )-which establishes a definitive correlation between KRAS* and SDC1 expression in PDAC development.
To determine whether SDC1 is required for disease progression, we depleted SDC1 in independent iKras* cultures. SDC1 depletion with shRNAs markedly impaired colony-forming ability ( Fig. 2a and Extended Data Fig. 4a-c) , which was rescued with the expression of shRNA-resistant Sdc1 (Extended Data Fig. 4d ). SDC1 depletion also significantly inhibited tumour growth of subcutaneous xenografts ( Fig. 2b and Extended Data Fig. 4e ). Additionally, CRISPR-mediated Sdc1 deletion in iKras* tumour cells suppressed colony formation and tumorigenicity in vivo (Fig. 2c, d and Extended Data Fig. 4f-h ). Consistent with mouse PDAC models, shRNA-mediated depletion of SDC1 in two established human PDAC cell lines, AsPC1 and HPAFII, as well as in the patient-derived xenograft (PDX) model PATC69 significantly impaired colony formation and suppressed tumour growth in vivo (Fig. 2e, f and Extended Data Fig. 4i-k) .
We investigated the role of SDC1 in KRAS*-driven PDAC development by generating p48-cre-LSL-Kras G12D p53 L/+ (also known as KPC) mice homozygous or heterozygous for the Sdc1-null allele. As previously reported 13 ,
Sdc1
−/− mice show normal postnatal development. In the PDAC model, Sdc1 deficiency prolonged survival relative to wildtype mice ( Fig. 2g ; 25 versus 16.75 weeks, respectively, P < 0.0001) and-notably-median survival was also comparably extended in Sdc1 +/− mice (24.3 weeks), which suggests a haploinsufficient phenotype. Flow cytometry analysis confirmed that SDC1 is expressed in Sdc1 +/− tumours, albeit at significantly reduced levels relative to Sdc1 +/+ tumours (Extended Data Fig. 5a ). Morphologically, Sdc1
and Sdc1 +/− tumours exhibited more well-differentiated ductal features accompanied by cystic lesions compared with Sdc1 +/+ tumours. Both Sdc1 −/− and Sdc1 −/+ tumours showed decreased tumour cell proliferation ( Fig. 2h and data not shown) and less aggressive phenotypes, with distal metastases to lung or liver observed in 5% and 4.2% of mice, respectively, compared with 31% in Sdc1 +/+ mice (Fig. 2i ). Of note, Sdc1 −/− tumours exhibited significantly decreased infiltration of myeloid-derived suppressor cells versus Sdc1 +/+ lesions (Extended Data Fig. 5b, c) .
We investigated the requirement of major KRAS* surrogate for the surface expression of SDC1. Treatment of iKras* cells with either of two distinct MEK inhibitors (AZD8330 or trametinib), but not with a pan-PI3K inhibitor (BKM120), decreased membrane SDC1 expression in a dose-dependent manner, similar to the effect of KRAS* extinction ( Fig. 3a and Extended Data Fig. 6a-f G12D inactivation were identified using SILAC-based proteomic analysis. In vivo loss-of-function screening was subsequently conducted with a custom barcoded lentiviral shRNA library targeting the KRAS*-dependent surfaceome. Depletion was observed relative to the reference population (Ref.) . b, Top-ten canonical signalling pathways identified with IPA analysis of differentially expressed surface proteins upon KRAS* activation; n = 3 biologically independent samples, enrichment score (Enrich.) and P value (two-sided Fisher test; Fisher) are reported. c, Rank of common top-scoring hits from three independent iKras* p53 L/+ tumour cell lines. Cut-off based on redundant shRNA activity (RSA) algorithms and logP is shown in the heat map alongside corresponding quantification rank from SILACbased proteomic analysis. d, Mass spectrum of a representative SDC1 peptide shows membrane SDC1 in the presence (heavy) or absence (light) of KRAS(G12D) in iKras* p53 L/+ tumour cells. e, SDC1 levels in iKras* p53 L/+ tumour cells in the presence (ON) or absence (OFF) of doxycycline were measured by fluorescence-activated cell sorting (FACS) (top) using an APC-conjugated SDC1 antibody, with quantification of mean fluorescence intensity (MFI) (bottom). ReON, cells were grown without doxycycline for 48 h, and then with doxycycline for 24 h (n = 3 biological replicates; data are mean ± s.d.; P values were determined by paired twosided Student's t-test). f, Three-week-old iKras* p53 L/+ mice received doxycycline-containing water for one, three or seven weeks to induce premalignant lesions or for nine weeks to induce invasive PDAC (T), then doxycycline was withdrawn for one, two or seven days. SDC1 in pancreatic or tumour tissues was analysed by immunohistochemistry. PT, peritumour region. Arrows indicate areas magnified in the insets. Scale bar, 200 µm. d-f, Representative experiments from three independent experiments.
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Extended Data Fig. 6a, b) , which indicates that KRAS* drives SDC1 membrane localization through the MAPK pathway.
Membrane SDC1 expression is primarily modulated via shedding 14 (proteolytic cleavage of the N-terminal domain into the extracellular space) and endocytosis 15 (internalization through the endocytic route, which is balanced by endosomal recycling that returns much of the endocytosed proteins back to the cell surface) 16 . Using enzyme-linked immunosorbent assay to detect shed SDC1 from iKras* cells upon doxycycline withdrawal, we determined that KRAS* extinction inhibited rather than enhanced SDC1 shedding in a time-dependent manner (Extended Data Fig. 6g ). Next, we used monovalent anti-syndecan antibodies, which are internalized in a syndecan-dependent manner and with comparable kinetics to bivalent antibodies 16 , with flow cytometry to measure changes in SDC1 internalization and recycling rates upon oncogene extinction. Whereas KRAS* extinction did not affect SDC1 internalization (Extended Data Fig. 6h ), the rate of SDC1 recycling back to the plasma membrane was significantly inhibited in the absence of KRAS* (Extended Data Fig. 6i, j) . To validate this result, we removed the ectodomain of preexisting cell-surface-exposed SDC1 by trypsinization and then measured trafficking of endocytosed SDC1 to the cell surface using an antibody that recognizes the SDC1 ectodomain. Recovery of surface SDC1 expression was significantly delayed upon KRAS* inactivation (Fig. 3b) , further supporting that KRAS* promotes SDC1 membrane localization by enhancing SDC1 recycling.
Trafficking of syndecan proteins to the plasma membrane is orchestrated by the small GTPase, ARF6 16 . KRAS* inactivation resulted in redistribution of SDC1 from the cell surface to the juxtanuclear ARF6 endocytic recycling compartment (Fig. 3c) , a characteristic of reduced ARF6 activity 16 . Indeed, as previously reported 17 , ARF6 activity was suppressed upon KRAS* extinction or treatment with the MEK inhibitor AZD8330 (Extended Data Fig. 7a ). Type I phosphatidylinositol 4-phosphate 5-kinase (PIPK) is a downstream effector of ARF6 18 ; PIPK activity was also inhibited upon KRAS* inactivation or MEK inhibition (Extended Data Fig. 7b ). Moreover, expression of the constitutively active ARF6(Q67L) mutant in iKras* cells caused membrane ruffling and rescued the decrease in SDC1 membrane localization on KRAS* extinction, whereas expression of the dominant-negative ARF6(T27N) inhibited SDC1 membrane localization in the presence of KRAS* (Extended Data Fig. 7c -e). We therefore conclude that KRAS* signalling stimulates ARF6 activity to promote SDC1 trafficking to the plasma membrane.
ARF6 activity is controlled by specific guanine nucleotide exchange factors and GTPase-activating proteins. We mined the expression profiles of iKras* tumour cells following KRAS* extinction 7 for ARF6-specific guanine nucleotide exchange factors and GTPase-activating proteins, and found that expression of the ARF6-specific guanine nucleotide exchange factor 'pleckstrin and Sec7 domain-containing 4' (PSD4), was significantly decreased upon KRAS* extinction (Extended Data Fig. 7f ). This was validated using quantitative PCR Relative MFI with reverse transcription; both KRAS* extinction and MEK inhibitor treatment markedly inhibited PSD4 expression (Extended Data Fig. 7g ). Moreover, PSD4 protein levels decreased in a time-dependent manner upon KRAS* extinction and were restored upon re-induction of KRAS* expression (Fig. 3d) . MEK inhibition, but not PI3K inhibition, blocked the increase in PSD4 protein on re-expression of KRAS*. Similarly, genetic KRAS* depletion or MEK inhibitor treatment in human PDAC MiaPaCa-2 cells both decreased PSD4 levels, whereas PI3K inhibition had no effect (Extended Data Fig. 7h ). Ectopic PSD4 expression in iKras* cells rescued the suppressed ARF6 activity (Extended Data Fig. 7i ) and the decreased surface SDC1 expression upon KRAS* extinction (Extended Data Fig. 7j ), which demonstrates that KRAS* regulates SDC1 surface localization via the PSD4-ARF6 axis.
The ability to stimulate macropinocytosis, a regulated form of endocytosis, is a distinctive feature of KRAS* activation 19 , and PDAC cells containing KRAS* rely on increased macropinocytosis for nutrient salvage to sustain uncontrolled growth 20 . Macropinocytosis was also among the enriched pathways identified by IPA of the KRAS*-regulated surfaceome (Supplementary Table 3 ). These data, coupled with reports that EFA6-mediated ARF6 activation can induce formation of plasma membrane protrusions and macropinocytosis 21, 22 , prompted us to investigate whether the KRAS*-dependent surface localization of SDC1 via the PSD4-ARF6 axis might regulate macropinocytosis. Consistent with previous findings 20 , iKras* tumour cells exhibited high levels of macropinocytosis, as measured by uptake of tetramethylrhodamine-labelled dextran (TMR-dextran). Macropinocytosis was substantially inhibited upon KRAS* inactivation or treatment with the macropinocytosis inhibitor EIPA (Extended Data Fig. 8a, b) , as well as in SDC1-depleted mouse PDAC cells derived from iKras* or KPC models (Fig. 4a, b and Extended Data Fig. 8c, d ). As anticipated, overexpression of SDC1 or PSD4 attenuated the decrease in macropinocytosis upon KRAS* extinction ( Fig. 4c and Extended Data Fig. 8e-g ), consistent with SDC1 membrane localization control by PSD4-ARF6 as an essential mechanism by which KRAS* drives macropinocytosis in PDAC.
The small GTPase RAC1 has a crucial role in the formation of initial membrane ruffles and macropinocytosis 23 . RAC1 activity was markedly inhibited in SDC1-depleted iKras* cells (Fig. 4d) , whereas RhoA activity remained unaffected (Extended Data Fig. 8h) . Moreover, ectopic expression of constitutively active RAC1 (RAC1(Q61L)) in SDC1-depleted iKras* tumour cells rescued macropinocytosis activity (Extended Data Fig. 8i-k) , supporting an essential role for RAC1 in SDC1-mediated macropinocytosis.
An essential function of macropinocytosis in PDAC cells is to take up proteins from the extracellular space to provide a supply of amino acids, including glutamine, to fuel metabolism 20 . Correspondingly, we found that culturing iKras* cells in low-glutamine medium (less than 0.5 mM) resulted in decreased proliferative capacity (Extended Data  Fig. 8l ). Albumin is taken up by cells via macropinocytosis and can rescue cell proliferation in low-glutamine conditions; it can therefore be used to functionally measure macropinocytosis 20 . SDC1 depletion reduced the effectiveness with which albumin rescued cell proliferation in iKras* tumour cells grown in low-glutamine conditions (Fig. 4e) , providing additional support for the critical role of SDC1 in maintaining macropinocytosis in PDAC cells.
To identify SDC1 domains required for RAC1 activation and macropinocytosis, we constructed a series of truncation mutants of SDC1 24, 25 that were expressed on the cell surface, as well as for soluble SDC1 protein, which was detected in the culture medium because it lacks the transmembrane and intra-cellular domains (Extended Data  Fig. 9a, b) . As expected, expression of full-length SDC1 fully rescued RAC1 activity in SDC1-depleted cells. By contrast, soluble SDC1 did not reactivate RAC1 (Extended Data Fig. 9c ), which indicates that the membrane localization of SDC1 is essential for macropinocytosis. Deletion of the extracellular domain of SDC1 also abolished its activity towards RAC1. However, SDC1(GAG), in which the glycosaminoglycan chain modification sites are mutated, exerted a partial rescue effect (Extended Data Fig. 9c ), suggesting that glycosaminoglycan chain may not be essential for this function. Of note, the SDC1(C30) mutant, which lacks its PDZ binding domain, also failed to rescue RAC1 activity in SDC1-depleted cells (Extended Data Fig. 9c ). The mutant constructs exhibit similar ability to restore macropinocytosis and rescue the in vivo tumour growth of SDC1-deficient cells (Extended Data Fig. 9d-g ). The C terminus of SDC1 binds to the PDZ-domain containing protein syntenin, and this complex is involved in assembly of multimers that organize intracellular signal-transduction pathways 26 . Ablation of syntenin markedly inhibited RAC1 activity, suppressed macropinocytosis, and impaired clonogenic activity and tumour growth in KRAS*-driven PDAC cells (Extended Data Fig. 9h-m) , suggesting that the SDC1-syntenin complex is required to mediate extracellular-intracellular signalling to promote macropinocytosis and tumour growth in this context.
Finally, we validated the role of SDC1 in human AsPC1 and PDXderived PATC69 cells, in which SDC1 depletion impaired macropinocytosis; this was rescued by ectopic expression of shRNA-resistant mouse Sdc1 (Extended Data Fig. 10a-c) . Evaluation of macropinocytosis across 20 KRAS*-driven human PDAC models demonstrated that P = 0.014 P = 0.007 P = 0.001 Letter reSeArCH SDC1 abundance at the membrane was correlated with macropinocytosis (Extended Data Fig. 10d-f) . Thus, our data across a variety of models highlight the requirement for SDC1 to mediate macropinocytosis in KRAS*-driven PDAC (Fig. 4f) .
Although activation of macropinocytosis by KRAS* in transformed cells has long been established 19 , the molecular mechanisms that control this process have remained unknown. Here we provide evidence that SDC1 serves as a KRAS* effector that induces macropinocytosis in PDAC. To our knowledge, pharmacological inhibition of macropinocytosis has not been accomplished; the critical role for SDC1 to regulate macropinocytosis in KRAS*-driven PDAC suggests SDC1 as a target for therapeutic intervention. Monoclonal antibodies directed against SDC1 (CD138) are being tested for activity in multiple myeloma as antibody-drug conjugates, proving the feasibility of developing targeted therapeutics against this molecule.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-019-1062-1. . Mice were interbred and maintained on the FVB/C57Bl6 hybrid background in pathogen-free conditions at The University of Texas MD Anderson Cancer Center. No statistical methods were used to predetermine cohort size. Animals of both sexes were used in the experiments. Mice were fed with doxycycline water (doxycycline 2g/l, sucrose 20 g/l) where indicated. All manipulations were approved under Institutional Animal Care and Use Committee (IACUC) protocol 00001238. The maximum tumour size allowed by IACUC is 1.5cm in diameter. Experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. SILAC-based surface proteomic analysis. Cell lines derived from primary culture of the iKras* PDAC mouse model were grown in RPMI1640 (Gibco) containing 10% dialysed FBS (Invitrogen) and 1% penicillin-streptomycin cocktail for seven passages, with 13 C-lysine and 13 C-arginine for Kras-ON cells and with regular lysine and arginine for Kras-OFF cells according to the standard SILAC protocol 27 . The detailed procedure of enrichment of cell-surface proteins is described in 'Cell surface proteins preparation' . Library design and construction. The custom library of the KRAS-related surfaceome was constructed by using chip-based oligonucleotide synthesis and cloned into the pRSI16 lentiviral vector (Cellecta) as a pool. The shRNA sequence includes 2 G-U mismatches in the passenger strand, a 7-nucleotide loop and a 21-nucleotide targeting region. Targeting sequences were designed using a proprietary algorithm (Cellecta). The oligonucleotide corresponding to each shRNA was synthesized with a unique molecular barcode (18 nucleotides) for measuring representation by next-generation sequencing. For each gene, 10-12 different shRNAs were designed and included in the surfaceome library. In vivo shRNA screens. We performed the in vivo screen in an orthotopic xenograft mouse model of PDAC. Transduction efficiency was determined sample by sample as the percentage of GFP-positive cells two days after infection, as measured by FACS analysis. Large-scale infection of mouse GEMM-derived cells was conducted as previously described 12 . In brief, cells were plated with fresh medium containing 8 µg/ml polybrene and sufficient virus to guarantee a 15-30% infection rate, and more than 1,000× coverage of the surfaceome library, based on the preceding calculations. Following puromycin selection (2 µg/ml) over the course of 48 h, cells were trypsinized, pooled together, and a minimum of 1 × 10 6 cells were washed in PBS and frozen at −80 °C as a reference. The remaining cells for the in vivo studies were separated into independent tubes (triplicates), suspended in PBS:matrigel (1:1) solution and 10 6 cells per mouse were injected orthotopically into the pancreas of fourto-six-week-old female immunocompromised mice (NSG, The Jackson Laboratory). For each GEMM-derived cell line, the potential for sufficient in vivo representation of the surfaceome library, at the time of collection, was first determined through sufficient complexity coverage of a 2.75K empty barcoded library. Xenograft studies. Xenograft studies were carried out in NSG mice or NCr Nude mice (Taconic) and were approved by the MD Anderson IACUC under protocol number 00001238.
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No statistical methods were used to predetermine cohort size. For orthotopic xenografts, mice were anaesthetized using a ketamine-xylazine solution (150 mg/ kg-10 mg/kg). Shaved skin was disinfected with betadine and ethanol. Incisions were performed through the skin-subcutaneous and muscular-peritoneal layers. The spleen and tail of the pancreas were exposed and cells (in 50% matrigel, BD Bioscience) were directly injected in the tail of the pancreas. The muscular-peritoneal planes were closed by continuous resorbable sutures. The skin-subcutaneous planes were closed with interrupted resorbable sutures. Analgesia was achieved with buprenorphine (0.1mg/kg twice daily). For the subcutaneous xenografts, female homozygous NCr nude mice (Taconic) were injected subcutaneously in the flank at about eight weeks of age. Tumours were collected and the volume was calculated according to the formula: volume = 1/2 × (width 2 × length). All xenograft experiments were approved by the MD Anderson IACUC under protocol number 00001238. The maximal tumour size allowed by IACUC is 1.5 cm in diameter. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Screen hit analysis. Read counting was performed as previously described 12 . In brief, Illumina base calls were processed using CASAVA (v. 1.8.2) , and resulting reads were processed using our in-house pipeline. Raw FASTQ files are filtered for a 4-bp spacer (CGAA) starting at the 18th base allowing for one mismatch, such that only reads amplified from the shRNA barcode are used for further processing. Then, 23-40 bp of the above reads were extracted for targeting libraries, and 1-18 bp were extracted for the non-targeting library, and the number of reads aligned to each barcode was counted using SAMtools. Read counts were normalized for the amount of sequencing reads retrieved for each sample using library-size normalization (to 100 million reads). Using normalized counts, each sample was compared to its respective reference and a fold change (expressed in log 2 ) was calculated. RSA was used to summarize the effect of knockdown at gene level.
CRISPR-Cas9

D10A
-nickase-based knockout. Cells was transfected with plasmids containing Cas9 D10A and Sdc1-targeting small guide RNAs (Santa Cruz). After 2 µg/ml puromycin selection for two weeks, single-cell clones were isolated and analysed by T7E1 assay and FACS analysis. The Sdc1 locus of SDC1-negative clones was amplified by PCR. For clones with a T7E1 cleavage pattern that is different from wild-type cells, PCR products of the Sdc1 locus were cloned into a vector for Sanger sequencing. For SDC1-negative clones, 12 individual bacteria transformants were randomly selected for sequencing. Clones 1 and 12 were validated as SDC1-null clones by FACS. All three Sdc1 loci of single clone 1 were further confirmed to be frameshifted by Sanger sequencing. All three Sdc1 loci of single clone 12 were confirmed to be modified by Cas9
. Two out of three loci were identified as frameshift or non-sense mutations and one was an in-frame deletion missing six nucleotides. Flow cytometry, cell sorting and endocytosis assay. Cells were suspended using Non-enzymatic Cell Dissociation Buffer (Sigma), pelleted and resuspended in cold PBS with 1% (w/v) BSA (BSA/PBS). To measure surface populations, resuspended cells were incubated with APC-conjugated anti-SDC1 or its isotype control antibody (Biolegend) for 15 min on ice and processed for flow cytometry analysis following the manufacturer's instructions. To measure total SDC1, resuspended cells were immediately fixed in PBS containing 1.6% polyformaldehyde (PFA) and permeabilized in 0.5% saponin before performing incubation with conjugated antibodies and processing for flow cytometry analysis as above. Propidium iodide was used to exclude dead cells. All samples were acquired using a BD FACSCantoII flow cytometer or BD LSRFortessa analyser. Cell sorting of the top 20% GFP-positive cells was performed using BD FACSAria cell sorter.
To measure endocytosis rates, cells were incubated with anti-SDC1 antibody (clone 281-2, Biolegend) on ice for 15 min to label the surface population of SDC1. Cells were washed with ice-cold growth medium and then incubated for the indicated times at 37 °C to allow internalization. At each time point, samples were immediately transferred to ice to halt trafficking and APC anti-rat IgG antibody was added to detect the anti-SDC1 remaining at the cell surface. Samples were then washed in ice-cold PBS-BSA, fixed, washed and analysed as described above. To measure recycling rate, cells were trypsinized at 37 °C to thoroughly remove surface SDC1 and washed with ice-cold growth medium. Cells were incubated at 37 °C for the indicated time points before being immediately cooled to 4 °C to arrest trafficking. Cells collected at sequential time points were incubated with APC-conjugated anti-SDC1 antibody, washed and analysed as described above. Statistical analysis. Pathway analysis of surfaceome data was performed using IPA software. Tumour volume and tumour-free survival were analysed using GraphPad Prism. Results from survival experiments were analysed with log-rank (Mantel-Cox) tests and expressed as Kaplan-Meier survival curves. Statistical analyses for comparison of grouped samples were performed using a two-way ANOVA test. Others comparisons were performed using the unpaired Student's test. Biological replicates that were drastic outliers owing to experimental variability were excluded. Error bars represent s.d. Cell culture. 293T, AsPC1, MIAPACA2, HPAFII, SW1990, HPAC, PANC1, CAPAN1, BXPC3, PANC0813 and PANC0327 cells were obtained from ATCC. DAN-G, HUPT3, HUPT4 and PATU8902 cells were obtained form DSMZ. SNU324 was obtained from AcceGen Biotech. KP4 was obtained from JCRB. All cell lines were authenticated with short tandem repeat profiling. Cells were cultured according to recommended protocols and tested negative for mycoplasma contamination. Establishment of primary PDAC lines was performed as previously described 5, 28 . Mouse-derived primary pancreatic cancer cells were maintained in RPMI-1640 medium containing 10% Tet-approved FBS (Clontech) and 1 mg/ml doxycycline (Clontech). Cell-surface protein preparation. To isolate cell-surface proteins, ~2 × 10 8 cells were biotinylated in the culture plate with 10 ml of 0.25 mg/ml of sulfo-NHS-SSbiotin (Thermo Scientific) in PBS at room temperature (23-24 °C) for 10 min, after extensive PBS rinsing. The residual biotinylation reagent was quenched with 10 mM lysine. Protein extraction was performed in a solution containing 3% (v/v) n-octylglucoside (Sigma-Aldrich) with cell disruption by sonication followed by centrifugation at 20,000g. Biotinylated proteins were chromatographically isolated by affinity chromatography using 1 ml NeutrAvidin Plus UltraLink Resin (Pierce) according to the manufacturer's instructions. Proteins bound to the column were recovered by reduction of the biotinylation reagent with 5 ml of solution containing 65 µmol DTT and 1% n-octylglucoside detergent overnight at 4 °C. A total of 0.3 mg of cell-surface proteins were reduced in DTT and alkylated with acrylamide before fractionation with reverse-phase high-performance liquid chromatography (RP-HPLC). To obtain whole-cell extracts for normalization, ~2 × 10 7 cells were lysed in 1 ml PBS containing n-octyl-glucoside (1% w/v) and protease inhibitors (complete protease inhibitor cocktail, Roche Diagnostics), followed by sonication and centrifugation at 20,000g with collection of the supernatant and Letter reSeArCH filtration through a 0.22-µm filter. Cells and debris were removed by centrifugation at 5,000g and filtration through a 0.22-µm filter. Mass spectrometry analysis. Samples were next fractionated at the protein level by reverse-phase chromatography followed by desalting for 5 min with 95% mobilephase A (0.1% trifluoroacetic acid (TFA) in 95% H 2 O) at a flow rate of 3 ml/min. Proteins were eluted from the RPGS reversed-phase column (4.6 mm internal diameter × 150 mm, 15 µm, 1,000 Å; Column Technology) and collected into 24 fractions, at a flow rate of 2.1 ml/min with a gradient elution that included an increase from 5% to 70% mobile phase B (0.1% TFA in 95% acetonitrile) over 25 min, 70% to 95% mobile phase B for 3 min, a wash step to hold at 95% mobile phase B for 2 min, and a re-equilibration step at 95% mobile phase A for 5 min. The collected fractions from RP-HPLC were dried by lyophilization and subjected to in-solution digestion with trypsin dissolved in 100 mM aminonium bicarbonate containing 2% acetonitrile buffer.
The samples were reconstituted with acetonitrile:water:TFA (3:97:0.1, v/v/v) and individually analysed by LC-MS/MS in a Qexactive mass spectrometer coupled to an Easy nanoLC 1000 system (Thermo Scientific) using a 15-cm column (75-µm internal diameter, C18 3 µm, Column Technology) as a separation column, and Symmetry C18 180-µm internal diameter × 20 mm trap column (Waters) over a 120-min gradient. Mass spectrometer parameters were: spray voltage 3.0 kV, capillary temperature 275 °C, full scan MS of scan range 350-1,800 m/z, resolution 70,000, AGC target 3 × 10 6 , maximun IT 50 ms and data-dependent MS2 scan of resolution 17,500, AGC target 1 × 10 5 , maximum IT 100 ms and repeat count 10. Acquired mass spectrometry data were processed by Proteome Discover 1.4 (Thermo Scientific). The tandem mass spectra were searched against Uniprot human database using Sequest HT. A fixed modification of propionamide (+71.037114 Da) was added to Cys and a variable modification of oxidation (+15.994915 Da) was added to Met. SILAC heavy stable isotopes 13C6 (+6.020129) was added to Arg and Lys. The precursor mass tolerance was 10 p.p.m. and the fragment mass tolerance was 0.02 Da. The searched data was further processed with the 'target decoy PSM validator' function to filter with FDR 0.05. Ingenuity pathway analysis. The list of 221 KRAS-regulated genes from the SILAC screen was subjected to IPA to find pathways enriched in changed genes. The enrichment of changed genes in certain pathways using mouse plasma membrane genes only as a background to ensure the enrichment is not from plasma membrane genes per se. All mouse plasma membrane genes (about 3,000 genes) were subjected to IPA. For a certain pathway, the result from SILAC top genes was compared to that from all mouse plasma membrane genes by the Fisher exact test. An enrichment fold is calculated as per cent of pathway-related genes in the SILAC screen over the percent of pathway genes in all mouse plasma membrane genes. ORF constructs. Sdc1, Arf6 and Rac1 ORFs were cloned in pHAGE lentivirus vector (EF1a promoter-GW-Ires-egfp (GW, Gateway modified)). Lentivirus preparation. Lentiviral particles were packaged in 293T cells using second-generation packaging plasmids psPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid 12259). The cells were transfected using polyethylenimine (PEI) and supernatant was collected 48-72 h after transfection. The virus was concentrated using ultracentrifuge at 23,000 rpm for 3 h and added to target cells with 10 µg/ml of polybrene (Millipore). Concentrated virus was used fresh or stored at −80 °C for further applications. Clonogenic assay. Cells (500-2,000) were seeded into each well of 6-well plates in duplicates and incubated to allow colony formation for 2−3 weeks. The colonies were stained with 0.2% crystal violet in 80% methanol. Genomic DNA extraction and PCR for next-generation sequencing library production. Following collection of orthotopic tumours and additional pancreas tissue from NSG mice, samples were first weighed and stored in liquid nitrogen for processing. Frozen tumours were then finely minced using clean scalpels and suspended in lysis buffer without RNase. The samples were then further dissociated using a gentleMACS Dissociator (Miltenyi Biotec). Following dissociation, 10 µl RNase A (Thermo Scientific DNase and protease free, 10 mg/ml) and 50 µl SDS (Promega) were applied, followed by DNA shearing with a sterile 23¼ gauge needle. Total genomic DNA from each sample was then isolated through a phenol-chloroform extraction, and the DNA was precipitated using 90 µl NaOAc (3 M) and 720 µl isopropanol. Linearized acrylamide was applied to each reference to ensure optimal DNA precipitation for each reference sample. Precipitated DNA was washed in 70% ethanol once before being resuspended in DNase-free water overnight. Samples were shaken overnight at 1,000 rpm at room temperature to aid DNA resuspension.
The barcode sequences for each tumour and reference sample were amplified using a two-step PCR reaction as previously described 12 , and subsequently isolated from a 2% agarose gel. Primers used during the two-step PCR barcode amplification were based on sequences provided by Cellecta. The primers involved in the second PCR amplification included P5 and P7 adaptors for the illumina HiSeq 2000 platform. Two separate primer pairs were used in the two-step PCR reaction for the 2.75K empty barcode library and the shRNA library. As previously described 12 and based on the two-step PCR amplification strategy outlined by Cellecta, the forward and reverse primers used were as follows: F_HTS3 and 13K_R (Empty Library PCR1), Gx1_Bp and P5_NR2 (Empty Library PCR2), F2 and 13K_R(2) (shRNA Library PCR1), and P7_NF2 and P5_NR2 (shRNA Library PCR2). Three separate indexed primers were used in the second, or nested, PCR amplification for the purpose of sample multiplexing during sequencing. Immunohistochemistry and western blot analysis. Tissues were fixed in 10% formalin overnight, moved in 70% ethanol and embedded in paraffin. After cutting, immunohistochemical analysis was performed as described 5 . For western blot analysis, cells were lysed on ice using RIPA buffer (Boston BioProducts) supplemented with protease and phosphatase inhibitors (Roche). SDC1 western blot was conducted as previously reported 29 . Before removel of glycosaminoglycan chains, proteoglycans migrate as a heterodisperse smear in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteoglycan samples were digested with heparin lyases before analysis in gels. In brief, cells were collected into ice-cold lysis buffer and total protein was precipitated overnight at −20 °C in methanol and washed with −20 °C acetone. Soluble material was resuspended in lysase buffer containing 0.0001 units heparitinase (Amsbio) and 0.005 units chondroitin ABC lysase (Sigma) and were resolved by 4-12% SDS-PAGE, transferred to Immobilon-P PVDF and fixed in 0.05% glutaraldehyde (Sigma). Immunofluorescence and confocal microscope. Cells were grown on eight-well chamber slides (LabTek), fixed in PFA with or without permabilization in 0.5% saponin. Cells were further incubated with the primary antibody for 2 h at room temperature. Autofluorescence was quenched and nonspecific protein-protein interactions were blocked with 1% BSA/10% normal goat serum/0.3 M glycine. The secondary antibody was used at a 1/1,500 dilution for 40 min at room temperature. DAPI was used to stain the cell nuclei. Images were captured with an Olympus FV1000 confocal microscope system. Detection and quantification of macropinocytosis. Macropinocytic index was determined as described 30 . In brief, cells were seeded in eight-well chamber slides (LabTek). Twenty-four to forty-eight hours after cell seeding, cells were serumstarved for 12-18 h. Macropinosomes were marked using a high molecular weight TMR-dextran (Fina Biosolutions) uptake assay in which TMR-dextran was added to serum-free medium at a final concentration of 1 mg/ml for 35 min at 37 °C. At the end of the incubation period, cells were rinsed 5 times in cold PBS and immediately fixed in 4% polyformaldehyde. Nuclei were stained with DAPI and coverslips mounted onto slides using DAKO Mounting Medium (DAKO). Images were captured using an Olympus FV1000 confocal microscope system and analysed using the analyze particles feature in ImageJ (NIH). The total particle area per cell was determined from at least six fields that were randomly selected from different regions across the entirety of each sample. Glutamine-deprivation assay. Glutamine-deprivation assay was performed following previously published protocols 20 , modified as follows: cells were plated in a 96-well plate at a density of 500 cells per well in regular complete RPMI1640 medium containing 10% Tet-approved FBS and 1 mg/ml doxycycline. Eighteen hours after seeding, cell were washed with PBS three times and incubated in the glutamine-deprivation RPMI1640 medium (Gibco). Glutamine-free RPMI1640 medium was supplemented to the indicated concentration of glutamine with 10% dialysed FBS, 25mM HEPES and 1 mg/ml doxycycline. For some experimental groups, medium was supplemented with 0.2% BSA (Sigma) and 25 µM EIPA (Invitrogen), with vehicle-only controls containing DMSO alone. For all experiments, medium was replaced every 24 h. Viable cell counts were obtained using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega Corporation). Plates were then scanned with a PHERAstar FS (BMG Labtech) at 490 nm. Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Policy information about availability of computer code
Data collection
Mass spectrometry data was processed by Proteome Discover 1.4 (Thermo Scientific). Confocal immunofluorescence images were collected with FV10-ASW 4.0 (Olympus). FACS data were collected with BD FACSDiva (BD Biosciences). Illumina sequencing for the in vivo shRNA screen were processed with CASAVA (v. 1.8.2) .
Data analysis
Data analysis and statistical tests were done using Prism (GraphPad Prism 6) or Excell (Microsoft). Confocal immunofluorescence images were analyzed with ImageJ (ImageJ). IPA (Qiagen) were used for pathway analysis. FACS data was analyzed with FlowJo (v10, FlowJo) . RSA algorithms (Pubmed), Ggplots (CRAN), Bowtie2 (Pubmed), SAM tools (Pubmed), Flowr(BioRxiv), and R package (CRAN) were used for in vivo shRNA screen analysis. Proteome Discover 1.4 (Thermo Scientific) and Sequest HT were used for mass spectrometry data analysis.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. 293T, ASPC1, MIAPACA2, HPAFII, SW1990, HPAC, PANC1, CAPAN1, BXPC3, PANC0813 and PANC0327 were obtained from ATCC. DAN-G, HUPT3, HUPT4 and PATU8902 were obtained form DSMZ. SNU324 was obtained from AcceGen Biotech. KP4 was obtained from JCRB. Primary PDX lines were established from xenograft tumors maintained in nude mice. Primary mouse PDAC lines were established using primary tumors from the corresponding genetically engineered mouse models.
Authentication
All STR profiles of human PDAC cell lines have been verified at "Characterized Cell Line Core Facility" at the UT MD Anderson Cancer Center. The PDX lines will also be submitted to the "Characterized Cell Line Core Facility" and all unique STR profiles are then added to the database for future MD Anderson reference.
Mycoplasma contamination
All cells have been tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register) No such cell lines were used.
Research animals
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Animals/animal-derived materials This is reported in Methods. For genetically engineered mouse models, the following strains are used: TetO_Lox-StopLox-Kras-G12D (tetO_LKrasG12D), p48-Cre, Rosa26-Lsl-rtTA-Ires-Gfp (Rosa_rtTA) , Trp53Flox, Kras-LSL-G12D, Sdc1-KO. Mice were interbred and maintained on FVB/C57Bl6 hybrid background. Both male and female mice were used. Animals between 10-42 weeks were used for the endpoint analysis. Animals between 3-13 weeks were used for the serial analysis. For xenograft studies, NSG or NCr Nude mice were purchased from Taconic. Both male and female mice of 6-8 week of age were used.
Method-specific reporting n/a Involved in the study ChIP-seq Cell population abundance at least 10,000 cells were quantified.
Gating strategy unstained cells were used to set up the FSC/SSC gates. Samples stained with isotype control antibody were used to set up gate for positive/negative boundary.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
